Abbvie INC Form 4 insider transactions

AbbVie Director Robert J. Alpern acquired 33 stock equivalent units at $231.54 each on September 30, 2025, bringing his total beneficial ownership to 10,151 units.

AbbVie Inc. Director Edward J. Rapp acquired 145 stock equivalent units, increasing his beneficial ownership to 28,152 units.

AbbVie's Chief Operations Officer, Azita Saleki-Gerhardt, exercised stock options and subsequently sold an equal number of shares for a significant gain.

AbbVie Inc.'s EVP, Chief Business and Strategy Officer, Nicholas Donoghoe, sold over 13,000 shares of common stock for approximately $2.6 million in pre-planned transactions.

AbbVie Inc. Director Robert J. Alpern has acquired 40 additional stock equivalent units as part of his director compensation, increasing his total beneficial ownership to 10,038 units.

AbbVie Director Edward J. Rapp acquired 177 stock equivalent units valued at $185.62 per unit, increasing his beneficial ownership to 27,785 units, as part of director fee compensation.

AbbVie Inc. Director Susan E. Quaggin acquired 81 stock equivalent units on June 30, 2025, valued at $185.62 per unit, as part of director fees credited to a grantor trust.

Director Thomas J. Falk reports acquisition of 1,203 restricted stock units and indirect ownership of 3,000 common stock shares through a limited partnership.

Director Glenn F. Tilton reports acquisition of restricted stock units and disposition of common stock.

Director Thomas C. Freyman reports acquisition and disposal of AbbVie common stock and restricted stock units.

Director Frederick H. Waddell reports changes in beneficial ownership of AbbVie Inc. shares, including the acquisition of restricted stock units and disposal of shares.

Director Rebecca B. Roberts reports acquisition of 1,203 shares of AbbVie common stock through restricted stock units and disposal of 13,728 shares.

Director Susan E. Quaggin reports acquisition of 1,203 restricted stock units in AbbVie Inc.

Director Melody B. Meyer reports acquisition and disposal of AbbVie common stock and restricted stock units.

Director Brett J. Hart reports changes in beneficial ownership of AbbVie Inc. common stock, including the acquisition of restricted stock units and disposal of shares.

Director Jennifer L. Davis reports acquisition of 1,203 restricted stock units in AbbVie Inc.

Director William H.L. Burnside reports acquiring 1,203 shares of AbbVie common stock and disposing of an unspecified amount.

Director Roxanne S. Austin reports acquisition of restricted stock units and disposal of common stock.

Director Robert Alpern reports acquiring and disposing of AbbVie common stock and restricted stock units.

Director Edward J. Rapp reports acquisition of restricted stock units and correction of a previously filed form regarding AbbVie shares.

Director Robert J. Alpern reports acquisition of stock equivalent units in AbbVie through director fees and dividend reinvestment.

Director Richard Gonzalez reports a gift of 2,450 shares of AbbVie Inc. common stock.

Director Edward J. Rapp reports acquisition of AbbVie stock equivalent units through director fees credited to a grantor trust.

Director Susan E. Quaggin acquired 71 stock equivalent units of AbbVie Inc. through director fees credited to a grantor trust.

EVP and Chief Commercial Officer of AbbVie, Jeffrey R. Stewart, reports the exercise of stock options and subsequent sale of shares on March 31, 2025.

AbbVie's EVP and CFO, Scott T. Reents, sold 17,644 shares of common stock at an average price of $212.34 on March 14, 2025.

Kevin K. Buckbee, SVP and Controller at AbbVie Inc., reported disposing of 3,699 shares of common stock on February 28, 2025, to cover tax obligations.

Roopal Thakkar, EVP, R&D and CSO of AbbVie Inc., reported the disposal of 4,678 shares of common stock on February 28, 2025.

Nicholas Donoghoe, EVP, CHIEF BUS/STRAT OFFICER of AbbVie Inc., reports disposition of 11,230 shares of common stock on February 28, 2025.

Director Richard Gonzalez reports the sale of AbbVie shares and shares withheld for tax obligations.